We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold ...

Blueprint Medicines Corporation BPMC reported fourth-quarter 2024 adjusted loss of 79 cents per share, wider than the Zacks ...

NASDAQ BPMC opened at $92.25 on Friday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 52 week low of $80.42 and a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chemomab Therapeutics (CMMB – Research Report) ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.82 per share a year ago.

BLUEPRINT MEDICINES ($BPMC) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of -$0.79 per share, missing estimates of -$0. ...

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...

What Are the BATMMAAN Stocks? If you're ready to move beyond Magnificent Seven stocks, there's a new acronym on Wall Street with one key addition.